Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Calcipotriene Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Calcipotriene Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for topical calcipotriene products used to treat plaque psoriasis of the body or scalp. It applies to adults and, depending on formulation, pediatric patients aged 12 years and older.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCalcipotriene Prior Authorization
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateAug 18, 2020
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for calcipotriene for plaque psoriasis of the body or scalp.
    SourceLink
    POLICY UPDATE CHANGES

    The 2025 revision replaced the description of vitamin D2 with vitamin D3.

    The 2025 revision modified the dosage-form section and references.

    1Drug covered by the policy
    3Topical dosage-form categories
    12+Minimum pediatric age
    Twice dailyApplication frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2026
    Most recent annual review year

    Plaque Psoriasis Coverage Criteria

    Plaque Psoriasis Initial Coverage Criteria

    Covered for plaque psoriasis when the requested formulation and patient age match one of the following pathways.

    Eligible indication and formulation pathway

    • Adult cream or ointment pathway: The patient is an adult with plaque psoriasis of the body and the requested product is cream or ointment.
    • Adult solution pathway: The patient is an adult with plaque psoriasis of the scalp and the requested product is solution.
    • Foam pathway: The patient is 12 years of age or older, including adolescents and adults, with plaque psoriasis of the body or scalp and the requested product is foam.Age >=12 years

    Prior Authorization Submission

    Prior Authorization

    Submit PA with indication, age, site, and formulation

    Submit a prior authorization request for calcipotriene to treat plaque psoriasis of the body or scalp. Coverage depends on the patient’s age, affected site, and requested formulation.

    • Adults: cream or ointment for plaque psoriasis of the body; solution for plaque psoriasis of the scalp; or foam for plaque psoriasis of the body or scalp.
    • Patients aged 12 years and older, including adolescents and adults: foam for plaque psoriasis of the body or scalp.

    Clinical Background

    Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors. By regulating skin-cell production, it inhibits keratinocyte proliferation and enhances keratinocyte differentiation, helping normalize abnormal skin-cell growth and keratinization associated with plaque psoriasis.

    Key Definitions

    Calcipotriene
    DefinitionA synthetic vitamin D3 analog.
    MechanismBinds to vitamin D receptors.
    Effect on skin cellsRegulates skin-cell production, inhibits keratinocyte proliferation, and enhances keratinocyte differentiation.
    Plaque psoriasis
    DefinitionA chronic inflammatory skin disease characterized by plaque involvement.
    Body involvementThe policy covers plaque psoriasis of the body, including treatment with cream or ointment in adults and foam in patients age 12 years and older.
    Scalp involvement

    Initial Treatment Requirements

    Initial Therapy for Plaque Psoriasis

    Initial treatment is covered for plaque psoriasis when the formulation and patient age meet the applicable criteria.

    Initial therapy pathways

    • Body plaque psoriasis: Plaque psoriasis affects the body and the requested formulation is cream or ointment for an adult, or foam for a patient 12 years of age or older.
    • Scalp plaque psoriasis: Plaque psoriasis affects the scalp and the requested formulation is solution for an adult, or foam for a patient 12 years of age or older.Age >=12 years for foam pathway
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCalcipotriene Prior Authorization
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateAug 18, 2020
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for calcipotriene for plaque psoriasis of the body or scalp.
    SourceLink
    On This Page
    Plaque Psoriasis Coverage CriteriaPrior Authorization SubmissionClinical BackgroundKey DefinitionsInitial Treatment Requirements
    The policy covers plaque psoriasis of the scalp, including treatment with solution in adults and foam in patients age 12 years and older.